VivoSeq
Oncology

Metastatic Bladder Urothelial Carcinoma

5

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Metastatic Bladder Urothelial Carcinoma is an early-stage landscape with 5 programs across 5 companies. The most active players are Avyxa, Eisai, Gynecologic Oncology Group. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

75/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 3Eisai logo

Eisai

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3Teva logo

Teva

1 program

Phase 3Gilead logo

Gilead

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSAntibody–drug conjugate120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT04579224·184 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)